Global Bio-pharma Market Research Report 2021

The global Bio-pharma market was valued at US$ XX million in 2020 and is expected to reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2021-2027.
This report focuses on Bio-pharma volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Bio-pharma market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Bio-pharma Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Monoclonal Antibodies
Recombinant Proteins
Granulocyte-Colony Stimulating Factor (G-CSF)
Interferons
Recombinant Human Insulin
Erythropoietin
Vaccines
Growth Hormones
Purified Proteins
Others

Segment by Application
Metabolic Disorders
Oncology
Neurological Disorders
Cardiovascular Diseases
Inflammatory and Infectious Diseases
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Pfizer
F. Hoffmann-La Roche AG
Johnson & Johnson Services
Sanofi, Amgen
AbbVie
Merck & Co., Inc
Biogen Idec
Bayer AG
Eli Lilly and Company
Novartis AG GlaxoSmithKline Plc
Bristol-Myers Squibb Company
AstraZeneca PLC
Abbott Laboratories